Introduction
Angiotensin-converting enzyme (ACE) is one of the limiting enzymes in the renin-angiotensinaldosterone system (RAAS). An elevated angiotensin II level causes deleterious effects on renal haemodynamics and induces the expression of different growth factors, leading to glomerulosclerosis. 1 Idiopathic nephrotic syndrome (INS) is one of the commonest renal problems in children encountered in day-to-day nephrology practice. Children with INS can be classified into welldefined categories based on the response to standard prednisolone therapy. 2 Clinically, the best prognostic indicator is whether or not the disease responds to steroid treatment. 3 It is, however, difficult to predict the course of the disease in terms of steroid responsiveness or steroid resistance. 4 ACE inhibitors and angiotensin receptor blockers reduce proteinuria in patients with nephrotic syndrome, 5 stressing the role of the RAAS in the pathogenesis of nephritic syndrome. A polymorphism of the ACE gene, consisting of a 287-base pair fragment within intron 16 defined by insertion (I) or deletion (D), has been shown to influence the circulating and cellular ACE concentration. 6, 7 The ACE gene I/D polymorphism is reportedly associated with the progression of several renal diseases, including diabetic nephropathy, IgA nephropathy, autosomal dominant polycystic kidney disease, and graft failure in renal transplant recipients. [8] [9] [10] [11] The D allele has a dominant effect and is associated with higher plasma ACE and angiotensin II levels. 2 The aim of this study was to determine the ACE I/D genotype distribution in children with nephrotic syndrome and to evaluate its effect on clinical, laboratory and pathological parameters in addition to the therapeutic response.
Patients and methods
Definitions INS was diagnosed by oedema, hyperlipidaemia, serum albumin below 2.5 g/dl and urinary protein excretion greater than 40 mg/m 2 /h. Proteinuria was considered to be in the nephrotic range Effect of angiotensin-converting enzyme gene insertion/ deletion polymorphism on steroid resistance in Egyptian children with idiopathic nephrotic syndrome Maha Saber-Ayad, * Samar Sabry, † Inas Abdel-Latif, # Hanaa Nabil, * when the urine protein was 3+/4+ on a dipstick test, spot albumin/creatinine ratio > 2 mg/mg, or urine albumin > 40 mg/m 2 /h (on a timed sample). Remission was defined as urine spot protein/creatinine of < 0.2 or absence of proteinuria on routine analysis. 3 Regarding renal function, the patients were classified as having either stable renal function or declining renal function (DRF). DRF was defined as doubling of serum creatinine from the onset of the nephrotic syndrome to the time of the study. 12 Clinical and laboratory parameters, including hypertension at presentation (blood pressure above 95 th percentile for age and sex), renal functions (blood urea nitrogen and creatinine), serum albumin and cholesterol, albumin/creatinine ratio, and 24-h urinary proteins, were assessed.
Steroid sensitive (SS) was defined as remission after a 4-week course of full-dose prednisolone treatment; whereas steroid non-sensitive (non-SS) was further subdivided into steroid resistant: persistence of proteinuria after a 4-week course of full-dose prednisolone treatment 3 and steroid dependent: relapse with switch of steroids to alternate day/tapering regimen or within 2 weeks of steroid withdrawal. 2
Patients and controls
The study included 51 patients with nephrotic syndrome followed up in the Nephrology Clinic, Children's Hospital, Cairo University. All patients had an age of onset ranging from 1-15 years and a regular follow-up period of a minimum of 6 months. Patients with secondary or familial nephrotic syndrome were excluded from the study. Fifty unrelated healthy normotensive adults with no renal diseases were enrolled in the study as a control group (age range: 22-30 years).
All patients received oral prednisolone. The initial episode of nephrotic syndrome was treated with prednisolone in a dose of 2 mg/kg/day in three divided doses for 4 weeks (6 weeks in the case of steroid non-responsiveness), followed by a single 2 mg/kg dose in the morning of every other day for 4 weeks. Then, the alternate-day treatment continued, but the dose was reduced by 12.5% every 2 weeks for the following 3-4 months. Relapses were treated with prednisolone in a daily dose of 2 mg/kg until the urine was free from protein for 3 days, followed by 4 weeks of alternate-day therapy and subsequently by 3-4 months of tapering course. 2
Genotyping of the ACE gene I/D polymorphism
After obtaining informed consent for inclusion into the study from the parents, genomic DNA was extracted from 200 µl of whole blood with EZ-10 Spin column DNA extraction minipreps kit (Biobasic Company, Canada). The I/D polymorphism of the ACE gene was determined according to the method of Rigat et al. 6 The sequences of the sense and antisense primers were 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and 5'-GAT GTG GCC ATC ACA TTC GTC AGA T-3', respectively (prepared by AM-Egypt). PCR was performed in a final volume of 50 µl that contained 25 µl master mix, ≈500 ng of genomic DNA, 12.5 pmol of each primer and 5% dimethylsulphoxide (DMSO). Amplification was performed using a Gene Amp PCR system 2400-Perkin Elmer. Samples were denatured for 1 minute at 94°C and then cycled 30 times through the following steps: 45 seconds at 94°C, 1 minute at 62°C, and 1 minute at 72°C. PCR products were electrophoresed in 1.6% agarose gel and visualised directly with ethidium bromide staining. The I allele was detected as a 490-bp band, and the D allele was detected as a 190-bp band (figure 1). DMSO was included in the PCR to prevent underestimation of heterozygotes and overestimation of the DD genotype. A second PCR amplification was performed for each DD type with a primer pair that recognises an insertion-specific sequence (5'-TGG GAC CAC AGC GCC CGC CAC TAC-3'; 5'-TCG CCA GCC CTC CCA TGC CCA TAA-3'), with identical PCR conditions except for an annealing temperature of 67°C and the absence of 5% DMSO. 13
Statistical analysis
The allele distribution of the ACE gene I/D polymorphism was tested for Hardy-Weinberg equilibrium in patient and control groups. A computer software package (SPSS), version 15, was used in the analysis. For quantitative variables, mean and median (as a measure of central tendency), standard deviation, range, minimum and maximum (as measures of variability) are presented. Frequency and percentage are presented for qualitative variables. Chi square and Fisher's Exact were used to estimate differences in qualitative variables. A p value of < 0.05 was considered to be statistically significant.
Results
Out of 51 children with INS recruited for the study, 37 were males (72.5%) and 14 were females (27.5%), and their age ranged from 1-15 years with a mean of 4.7±2.9 years. Twenty children Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore (39.2%) were SS and 31 (60.8%) were non-SS. Among the non-SS patients, 18 were steroid dependent and 13 were steroid resistant. The demographic, clinical, and laboratory findings of the patients are shown in table 1. Hypertension at presentation was significantly more frequent in the non-SS patients than in the SS patients.
In the genetic study for ACE I/D genotype distribution, the incidences for II, ID, and DD genotypes in the entire group of patients were 10 (19.6%), 36 (70.6%), and 5 (9.8%), respectively. The incidences of II, ID, and DD in controls were 6 (12%), 34 (68%), and 10 (20%), respectively. The differences between controls versus the entire patient group, the SS group, and the non-SS group were not statistically significant (p value > 0.05 for all comparisons). According to the Hardy-Weinberg equation (I+D) 2 = 1, this gave rise to (0.28+0.5+0.22) for the patient group and (0.23+0.5+0.27) for the control group.
For the SS group, the corresponding incidences were 4 (20%), 13 (65%), and 3 (15%), respectively, while for the non-SS group the corresponding incidences were 6 (19.4%), 23 (74.2%), and 2 (6.5%), respectively (figure 2). The difference between the SS group and the non-SS group was statistically insignificant (p>0.05).
In terms of the presence or absence of the D allele, the D+ genotype (ID+DD) was present in 41 subjects of the entire patient group (80.4%), whereas the D-genotype was present in only 10 patients (19.6%). The frequency of the D+ genotype was 80.0% (16/20) in the SS group compared to 80.6% (25/31) in the non-SS group (table 2) ; the difference between the two groups was statistically insignificant (Fisher's Exact=1). The D+ genotype was present in 88% of controls, which was statistically insignificant as compared to the patients (p value > 0.05).
In terms of DD and non-DD genotypes, the frequency of the DD genotype in the entire patient group was 9.8% (n=5), while the frequency of the non-DD genotype was 90.2% (n=46). The 
Figure 2
Distribution of the different genotypes in the SS group versus the non-SS group. Among 31 patients with an age of onset of less than 4 years, the frequencies of the II, ID, and DD genotypes of the ACE gene were 16.1% (n=5), 71.0% (n=22), and 12.9% (n=4), respectively; while among 20 patients with an age of onset of more than 4 years, the frequencies were 25% (n=5), 70% (n=14), and 5% (n=1), respectively. The differences between the two groups were statistically insignificant (Chi square=0.788, p>0.05).
Among 42 normotensive patients at presentation, the frequencies of the II, ID, and DD genotypes of the ACE gene were 21.4% (n=9), 69.0% (n=29), and 9.5% (n=4); while among 9 patients with hypertension at presentation, the frequencies were 11.1% (n=1), 77.8% (n=7), and 11.1% (n=1), respectively. The differences between the two groups were statistically insignificant (Chi square=0.801, p>0.05).
At the end of the study, 41 patients had stable renal function while 10 showed DRF. The distribution of the II, ID, and DD genotypes in the patients with stable renal function was 19.5% (n=8), 70.7% (n=29), and 9.7% (n=4); while among the 10 patients with DRF, the frequencies were 20% (n=2), 70% (n=7), and 10% (n=1), respectively. The differences between the two groups were statistically insignificant (Chi square=0.965, p>0.05).
Percutaneous renal biopsy was carried out in 15 of the 51 patients included in the study. Five had n=2)]. However, the differences between the two groups were not statistically significant (Fisher's Exact=0.077) ( figure 3 ).
Discussion
The genetic origin of kidney diseases has been a focus of research in the past few years. There is significant evidence showing that the RAAS is involved in the pathogenesis of progressive renal disorders. As a matter of fact, in recent studies the association between disease progression and the ID/DD genotype of the ACE gene has been well described. 2 Interestingly, it has been found that patients with the DD genotype experienced a more severe clinical course. 12 INS is the most common glomerular disease in childhood, occurring with an annual incidence of 2-3 per 100,000. 13, 14 INS represents a heterogeneous group of glomerular disorders, and patients are generally divided into steroid-sensitive and steroid-resistant (SRNS). 15 It is difficult to predict at onset the clinical course in terms of steroid responsiveness or resistance. 3 Oral corticosteroids are the first line treatment for a child with INS. Although most children with INS respond to corticosteroid therapy, one half of them become steroid dependent (SDNS) with a clinical course stretched over many years. SDNS is defined as two consecutive relapses, which are not associated with concurrent infections while tapering steroids or within 14 days of stopping therapy. Continuation of long-term steroids in SDNS entails risk of serious side-effects. SRNS is defined as failure to achieve remission in spite of 4-week prednisolone therapy in the dose of 60 mg/m 2 /day. 16 The RAAS is considered likely to be one of the mechanisms that govern disease progression, and genetic polymorphisms of various components of this system have been associated with the clinical courses of several types of renal disease. Angiotensin II is the most active product of the RAAS and it has a strong influence on local and systemic haemodynamic regulation. Angiotensin II is also a renal growth factor that modulates key elements of renal disease progression, including renal mesangial cell growth, extracellular matrix synthesis, and degradation and inflammatory processes. The effects of angiotensin II are mediated by the release of several factors, including transforming growth factor-B, plasminogen activator inhibitor-1, monocyte chemoattractant protein-1, and the activation of various nuclear transcription factors, including activator protein-1 and nuclear factor κB. 15 The ACE DD genotype is associated with increased circulating ACE levels, which are generally two times as high as those found for the II genotype; ID heterozygotes are associated with intermediate ACE levels. 6 This study was undertaken to determine whether the I/D polymorphism of intron 16 of the ACE gene can affect the pattern of response to steroid therapy. Introducing alternative therapies in the new protocols for treatment of SDNS and SRNS makes it of high importance to recognise the patients who are expected to have SDNS or SRNS through investigating their genes. In the future, the availability of gene chips will save time and money as the modality of therapy will be selected according to the patient's genotype, using different genes that are known to affect the response.
The present study was carried out on 51 Egyptian patients with INS and 50 unrelated healthy controls. The results showed a significant relation between the presence of hypertension on presentation and non-SS pattern. Out of 9 patients with hypertension on presentation, 8 (88.9%) were steroid non-responsive (p<0.05). Also, more patients in the non-SS group showed declining of renal functions at the end of the study. Among 10 patients with declining renal functions, 30% (n=3) were SS and 70% (n=7) were non-SS. This coincides with the results of the study of Serdaroglu and co-workers where steroid resistance correlated significantly with lower glomerular filtration rate and hypertension was more prevalent in non-SS patients (although statistically non-significant). 15 In the current study, we tried to increase the specificity of ACE I/D genotyping by using DMSO in the first PCR. In addition, a second PCR was performed for the samples that showed DD genotype in the first step. Out of 43 patients who showed initially the DD genotype, 27 patients were proven to have the ID genotype after the use of DMSO. This was confirmed by the second PCR. 17 The results of this study revealed that out of the 51 patients studied, ID genotype carriers were most frequent 70.6% (n=36) compared to homozygous DD 9.8% (n=5) and II 19.6% (n=10). In terms of the presence or absence of the D allele, the frequency of the D+ genotype (ID+DD) was 80.4% (n=41) and the frequency of the D-genotype (II) was 19.6% (n=10). In terms of DD and non-DD genotypes, the frequency of the DD genotype was 9.8% (n=5), while the frequency of the non-DD genotype was 90.2% (n=46). This is in agreement with the study of Rigat and his colleagues who estimated the distribution of the I/D polymorphism to be highest for the ID genotype (46%) compared to the DD genotype (36%) and II genotype (18%). 6 This stresses the fact that allelic distribution may differ according to the population under study.
The frequencies of the II, ID, and DD genotypes in controls were 12%, 68%, and 20%, respectively, which were statistically insignificant when compared to those of patients. This is in agreement with the study of Sasongko et al. who reported that the differences in the distribution of the ACE gene polymorphism between INS patients and controls were not statistically significant. 18 This is, however, in contrast with most other studies in which the DD genotype was significantly more common in nephrotic patients compared to normal individuals. 2, 4, 19 This may suggest an influence of ethnicity and other genes on the development of INS.
The key question at onset of INS is whether the patient will be steroid-sensitive or steroid-resistant. So far, there is no early diagnostic test that can provide a reliable answer. Although renal histology is helpful to predict the clinical course of INS in children, there are some limitations due to sampling. The present study in Egyptian children with INS did not demonstrate any significant correlation of the ACE gene I/D polymorphism with the pattern of steroid-responsiveness. These results are similar to some reports from other countries, for example, a study from Brazil did not find any significant correlation between ACE genotype and steroid-responsiveness. 20 Similar results were obtained in Japan by Hari and his colleagues, 18, 21 in a Kuwaiti population by Al-Eisa et al., 19 and in Switzerland by Bernd et al., 22 who reported identical ACE genotype distributions in steroid-responsive and -resistant patients. Serdaroglu et al. in a study done in a Turkish population found the same D allele frequencies in all steroid response groups. 15 In contrast to the present study is the work of Tsai and his colleagues in Taiwan; 3 the incidence of the DD genotype was significantly higher in the non-SS patients than in the SS patients.
Similarly, a study from Israel reported that they achieved remission in two thirds of children with the II genotype, but in only 24% of children with the DD and ID genotype. 12 They concluded that ACE genotype interfered with steroid response in the patients with FSGS. Lee and his colleagues reported in a Korean population a steroid response in 1/8 patients with the DD genotype and 5/18 patients with the other genotypes. 23 Patil and co-workers showed that in an Indian population, the II genotype was more frequent in steroid sensitive nephrotic syndrome children in comparison to normal controls. 4 In this study, there was no significant relation between the patient's genotype and the age of onset. In agreement with our study is that of Serdaroglu et al. done in a Turkish population. 15 In contrast, a Korean study 23 reported a younger age of onset for the DD genotype and a Kuwatian study 19 reported that the age of onset was 37 months for the DD genotype and 65 months for the II genotype.
Our study did not find a statistically significant relation between the patient's genotype and the susceptibility to develop hypertension. In agreement with our study, 23 Also, Al-Eisa et al. in Kuwait reported that the DD genotype was frequently seen in FSGS, but in that study only 3 patients had FSGS while the other patients exhibited several other histological appearances. 19 Highlights on the use of ACE inhibitors for FSGS patients give rise to the curiosity of ACE I/D polymorphism involvement in the course of FSGS. In fact, ACE antagonist administration has been reportedly beneficial for FSGS patients as it decreases urinary protein excretion and prevents progression to renal failure. 25 The response to cyclophosphamide was evaluated in 15 patients with non-SS nephritic syndrome. None of them had the DD genotype. In terms of the presence or absence of the D allele, the frequencies of D+ and D-genotypes were 40% (n=2) and 60% (n=3) in cyclophosphamide responders. The frequencies were 90% (n=9) and 10% (n=1) in cyclophosphamide non-responders, respectively (Fisher's Exact=0.077, statistically non-significant).
Although the results of the present study were not statistically significant as regards the effect of the ACE gene I/D polymorphism on the pattern of steroid responsiveness, histopathology or long-term clinical outcome, this study is a step in the direction of evaluating pharmacogenetics. When such studies are performed on a larger number of patients and extended to include other genes, they can have more predictive value, perhaps of statistical significance. In the future, with the development of new technologies that can shorten the time needed for genotyping, the dream of pharmacologists and clinicians will probably come true: the therapy will be tailored to every single patient according to his/her genotype.
Conclusion
The current study on Egyptian children with INS revealed no association between the ACE gene I/D polymorphism and clinical or histological findings, steroid resistance or progression of the disease. These results are at variance with reports from other parts of the world, suggesting that the impact of this ACE gene polymorphism on paediatric INS is likely to be influenced by ethnic origin. Results of this study revealed an association between hypertension at presentation and non-responsiveness to steroids, emphasising the highly important, but sometimes overlooked, role of repeated clinical evaluation. Patients with steroid non-responsiveness were more liable to develop impaired renal function.
